Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report

BACKGROUND: There is no established treatment for primary pulmonary lymphoepithelioma-like carcinoma (LELC) until now. CASE SUMMARY: In this study, the patient responded well to sintilimab combined with paclitaxel and carboplatin, showing no obvious side effects. Meantime, the values of carbohydrate...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Shu-Ying, Yuan, Jin, Lv, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649564/
https://www.ncbi.nlm.nih.gov/pubmed/36387802
http://dx.doi.org/10.12998/wjcc.v10.i31.11617
_version_ 1784827823895085056
author Zeng, Shu-Ying
Yuan, Jin
Lv, Min
author_facet Zeng, Shu-Ying
Yuan, Jin
Lv, Min
author_sort Zeng, Shu-Ying
collection PubMed
description BACKGROUND: There is no established treatment for primary pulmonary lymphoepithelioma-like carcinoma (LELC) until now. CASE SUMMARY: In this study, the patient responded well to sintilimab combined with paclitaxel and carboplatin, showing no obvious side effects. Meantime, the values of carbohydrate antigen 15-3 (CA15-3) and carbohydrate antigen 72-4 (CA72-4) gradually returned to normal. CONCLUSION: Immunotherapy combined with chemotherapy in advanced-stage LELC may be more effective than immunotherapy or chemotherapy alone. CA15-3 and CA72-4 are biomarkers for evaluating therapeutic effects for LELC.
format Online
Article
Text
id pubmed-9649564
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-96495642022-11-15 Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report Zeng, Shu-Ying Yuan, Jin Lv, Min World J Clin Cases Case Report BACKGROUND: There is no established treatment for primary pulmonary lymphoepithelioma-like carcinoma (LELC) until now. CASE SUMMARY: In this study, the patient responded well to sintilimab combined with paclitaxel and carboplatin, showing no obvious side effects. Meantime, the values of carbohydrate antigen 15-3 (CA15-3) and carbohydrate antigen 72-4 (CA72-4) gradually returned to normal. CONCLUSION: Immunotherapy combined with chemotherapy in advanced-stage LELC may be more effective than immunotherapy or chemotherapy alone. CA15-3 and CA72-4 are biomarkers for evaluating therapeutic effects for LELC. Baishideng Publishing Group Inc 2022-11-06 2022-11-06 /pmc/articles/PMC9649564/ /pubmed/36387802 http://dx.doi.org/10.12998/wjcc.v10.i31.11617 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Case Report
Zeng, Shu-Ying
Yuan, Jin
Lv, Min
Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report
title Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report
title_full Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report
title_fullStr Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report
title_full_unstemmed Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report
title_short Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report
title_sort favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649564/
https://www.ncbi.nlm.nih.gov/pubmed/36387802
http://dx.doi.org/10.12998/wjcc.v10.i31.11617
work_keys_str_mv AT zengshuying favorableresponseofprimarypulmonarylymphoepitheliomalikecarcinomatosintilimabcombinedwithchemotherapyacasereport
AT yuanjin favorableresponseofprimarypulmonarylymphoepitheliomalikecarcinomatosintilimabcombinedwithchemotherapyacasereport
AT lvmin favorableresponseofprimarypulmonarylymphoepitheliomalikecarcinomatosintilimabcombinedwithchemotherapyacasereport

Ejemplares similares